Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination effects of complement regulatory proteins and anti-complement polymer.

Yasuo Yoshioka1, Ryo Suzuki, Takayuki Okamoto

  • 1Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

Biochimica Et Biophysica Acta
|December 4, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemipelvectomy for Clostridium septicum necrotizing soft tissue infection with extensive pelvic organ destruction: a case report.

International journal of emergency medicine·2026
Same author

Early failure of primary repair of a Bochdalek diaphragmatic defect during retroperitoneal liposarcoma resection: a case report.

Journal of surgical case reports·2026
Same author

Impact of Acute Graft-Versus-Host Disease and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease after Letermovir Prophylaxis during the First 100 Days after Cord Blood Transplantation.

Transplantation and cellular therapy·2026
Same author

Incidence and Risk Factors for Ciliochoroidal Detachment Following Preserflo MicroShunt Implantation.

Journal of glaucoma·2026
Same author

Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography.

Communications biology·2026
Same author

Flow imaging for particle characterization and quantification in biologicals: A perspective from the Japanese Biopharmaceutical Consortium.

Journal of pharmaceutical sciences·2026

This study developed advanced cytomedicine using complement regulatory protein (CRP) and anti-complement agents. This novel approach significantly enhances protection for encapsulated cells against immune attack, improving cytomedical therapy potential.

Area of Science:

  • Biotechnology
  • Immunology
  • Regenerative Medicine

Background:

  • Current cytomedicine, using alginate-poly-L-lysine-alginate (APA) microcapsules, offers limited protection against humoral immune responses like xenograft rejection.
  • Humoral immunity, particularly the complement system, poses a significant threat to the viability of encapsulated therapeutic cells.

Purpose of the Study:

  • To develop a novel cytomedicine capable of protecting entrapped cells from complement-mediated injury.
  • To investigate the efficacy of incorporating a complement regulatory protein (CRP) and an anti-complement device into cytomedicine.

Main Methods:

  • Cells were transfected with the complement regulatory protein (CRP), Crry.
  • Crry-transfected cells were entrapped in agarose microbeads, some containing polyvinyl sulfate (PVS), a novel anti-complement agent.

Related Experiment Videos

  • The resistance of these constructs to complement-mediated injury was evaluated.

    • Main Results:

    • Crry-transfected cells in agarose microbeads showed partial resistance to complement.
    • Entrapment of Crry-transfected cells within agarose microbeads containing polyvinyl sulfate (PVS) provided significant protection against complement attack.
    • The combination therapy demonstrated superior anti-complement activity.

    Conclusions:

    • Combining a complement regulatory protein (CRP) with a cytomedical device possessing anti-complement activity offers enhanced protection for encapsulated cells.
    • This dual-component strategy represents a superior approach for advancing cytomedical therapy and overcoming immune rejection barriers.